Geode Capital Management LLC Grows Stock Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Geode Capital Management boosted its stake in Bristol Myers Squibb by 13.1% in the fourth quarter, adding more than 6 million shares and bringing its total holdings to 52.6 million shares worth about $2.84 billion.
• Bristol Myers Squibb reported stronger-than-expected quarterly results, with EPS of $1.58 versus estimates of $1.42 and revenue of $11.49 billion versus $10.93 billion expected. The company also reiterated FY 2026 guidance of $6.05 to $6.35 EPS.
• The company continues to offer an attractive dividend, paying a quarterly dividend of $0.63 per share, which annualizes to $2.52 and a yield of about 4.4%.

Geode Capital Management LLC increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 13.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,638,346 shares of the biopharmaceutical company's stock after buying an additional 6,084,046 shares during the period. Geode Capital Management LLC owned about 2.59% of Bristol Myers Squibb worth $2,837,026,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $25,000. Physician Wealth Advisors Inc. lifted its holdings in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $32,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Bristol Myers Squibb in the third quarter valued at about $35,000. Finally, Garner Asset Management Corp purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $35,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Down 0.7%

Shares of NYSE BMY opened at $57.63 on Thursday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm's 50 day moving average price is $58.42 and its 200 day moving average price is $56.18. The firm has a market cap of $117.68 billion, a P/E ratio of 16.19, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the business earned $1.80 earnings per share. Bristol Myers Squibb's revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 70.79%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BMY. Piper Sandler reaffirmed an "overweight" rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Citigroup reaffirmed a "neutral" rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Wall Street Zen raised shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Sunday, April 19th. HSBC upped their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a report on Tuesday, March 17th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $61.31.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company's stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.